Zentalis Pharmaceuticals Inc expected to post a loss of 92 cents a share - Earnings Preview

Zentalis Pharmaceuticals

26/02/2024 15:33

* Zentalis Pharmaceuticals Inc  ZNTL.OQ   ZNTL.O  is
expected
to show no change in quarterly revenue when it reports 
results on February 28 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Zentalis Pharmaceuticals
Inc
is for a loss of 92 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $32.50​, above​ its last closing price
of $13.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.91       -0.91      -0.79     Beat    13.3
 Jun. 30 2023  -1.02       -1.04      -1.85     Missed  -78.3
 Mar. 31 2023  -0.98       -1.02      -1.07     Missed  -5​
 Dec. 31 2022  -1.01       -1.06      -0.92     Beat    13.2
 ​​Sep.        -1.15       -1.17      -0.96     Beat    17.9
 30 2022                                                
 Jun. 30 2022  -1.18       -1.19      -1.34     Missed  -13​
 Mar. 31 2022  -1.21       -1.21      -1.31     Missed  -7.8
 Dec. 31 2021  -1.45       -1.49      -1.11     Beat    25.8
 This summary was machine generated February 26 at 15:33 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)